Sei Investments Co. Sells 6,318 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Sei Investments Co. trimmed its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 25.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,092 shares of the company’s stock after selling 6,318 shares during the period. Sei Investments Co.’s holdings in Dyne Therapeutics were worth $638,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the company. RA Capital Management L.P. bought a new position in shares of Dyne Therapeutics during the 1st quarter worth $140,666,000. Vanguard Group Inc. boosted its position in Dyne Therapeutics by 47.7% during the first quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after purchasing an additional 1,110,629 shares during the period. Janus Henderson Group PLC increased its stake in shares of Dyne Therapeutics by 23,512.0% in the first quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock worth $75,915,000 after purchasing an additional 2,663,910 shares in the last quarter. Artal Group S.A. raised its position in shares of Dyne Therapeutics by 24.6% in the first quarter. Artal Group S.A. now owns 1,517,960 shares of the company’s stock valued at $43,095,000 after purchasing an additional 300,000 shares during the period. Finally, Federated Hermes Inc. lifted its stake in shares of Dyne Therapeutics by 10.4% during the 2nd quarter. Federated Hermes Inc. now owns 1,215,112 shares of the company’s stock valued at $42,881,000 after buying an additional 114,888 shares in the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock opened at $33.13 on Wednesday. Dyne Therapeutics, Inc. has a fifty-two week low of $6.40 and a fifty-two week high of $47.45. The stock has a market cap of $2.89 billion, a P/E ratio of -8.35 and a beta of 1.05. The firm’s fifty day moving average price is $38.92 and its 200-day moving average price is $34.24.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.02. On average, analysts predict that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current year.

Insider Activity at Dyne Therapeutics

In other news, CEO John Cox bought 32,000 shares of the business’s stock in a transaction on Wednesday, September 4th. The stock was acquired at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the purchase, the chief executive officer now directly owns 8,000 shares in the company, valued at $264,320. This represents a -100.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Dyne Therapeutics news, CEO John Cox bought 32,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The shares were bought at an average price of $33.04 per share, for a total transaction of $1,057,280.00. Following the transaction, the chief executive officer now directly owns 8,000 shares in the company, valued at $264,320. This trade represents a -100.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Dirk Kersten sold 79,411 shares of the company’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the sale, the director now owns 234,127 shares of the company’s stock, valued at approximately $8,533,929.15. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 135,304 shares of company stock valued at $4,857,019. Corporate insiders own 20.77% of the company’s stock.

Wall Street Analyst Weigh In

DYN has been the subject of a number of recent research reports. Piper Sandler reiterated an “overweight” rating and issued a $53.00 price objective on shares of Dyne Therapeutics in a research note on Monday, September 23rd. Guggenheim boosted their price objective on Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, August 15th. Oppenheimer restated an “outperform” rating and issued a $55.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, September 4th. Finally, StockNews.com lowered shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. One investment analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Dyne Therapeutics has an average rating of “Moderate Buy” and an average target price of $51.40.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.